Wedbush Lifts Earnings Estimates for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities research analysts at Wedbush upped their Q3 2025 EPS estimates for Fennec Pharmaceuticals in a research report issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of $0.56 for the quarter, up from their previous forecast of $0.46. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.03 EPS and FY2027 earnings at $4.06 EPS.

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 0.2 %

Shares of FRX opened at C$8.93 on Tuesday. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.43. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The firm has a market capitalization of C$244.32 million, a P/E ratio of 89.30 and a beta of 0.25. The firm’s 50-day moving average is C$7.25 and its two-hundred day moving average is C$7.67.

Insiders Place Their Bets

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov bought 25,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was bought at an average price of C$3.87 per share, for a total transaction of C$96,840.00. Also, Senior Officer Robert Christopher Andrade purchased 15,816 shares of Fennec Pharmaceuticals stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88. Over the last ninety days, insiders have bought 41,612 shares of company stock worth $157,868. 16.20% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.